Jump to main content

Hereditary Angioedema Treatment

Man smiling with a group of friends.

Help manage the unpredictable and potentially life-threatening nature of hereditary angioedema (HAE) attacks and its impact on your patient's life—choose an effective management plan that helps prevent and reduce HAE attacks.1,2

Are you currently treating patients with HAE?

Craft an effective HAE management plan that prevents and reduces the frequency and severity of their HAE attacks.

For Internists

After confirming an HAE diagnosis, work with your patient to develop an effective management plan that prevents and reduces attacks—or connect your patient to an allergist/immunologist in your area with experience treating HAE.

For OB-GYNs

Remember to play an active role in your patient's management team as estrogen-containing medications, pregnancy, or menopause may be potential triggers.1

Collaboration icon.

The 2020 HAEA guidelines state that HAE management plans must be individualized with treatment tailored to each patient's medical needs, life circumstances, and preferences, as well as tolerance of and response to specific medications.1

Developing an HAE management plan

HAE document icon.

It's important to understand the impact of HAE on your patients. HAE management plans should be individualized with treatment tailored to each patient’s1:

  • Medical needs
  • Life circumstances
  • Preferences
  • Tolerance of and response to specific medications
Collaboration icon.

Collaboration between healthcare providers and their patients is key to ensure the impact of HAE on a patient's life is understood and shared goals of treatment outcomes are established1

Pharmaceutical cross icon.

Patients reporting difficulty with frequent, severe, or disruptive HAE attacks should be assessed for a dosage adjustment or alternative therapy1

Book icon.

As is the case with any chronic condition, patients (including young patients and their caregivers) should be educated about HAE1

Patients and their loved ones can visit DiscoverHAE.com to learn more about the condition.

On-demand treatment for HAE

  • On-demand or acute treatments can minimize morbidity and prevent mortality from an ongoing HAE attack1
  • All patients with HAE should have access to at least 2 doses of an on-demand medication with them at all times for the treatment of acute attacks 1
  • All attacks, irrespective of location, should be considered for treatment as soon as they are clearly recognized 1

Want to learn about one on-demand treatment?

Collaboration icon.

The benefits and potential adverse effects of HAE medications should be discussed in detail so that patients can make informed choices about their treatment.1

Preventive treatment for HAE

  • Preventive or long-term prophylactic (LTP) treatments help prevent HAE attacks before they occur.1
  • According to hereditary angioedema treatment guidelines, decisions regarding which patients should be considered for LTP should take into account the patient’s quality of life and treatment preference in the context of attack frequency, attack severity, comorbid conditions, and access to emergent treatment 1
  • Your patient’s needs and disease may change over time, and they may need a reminder that their management plan can change, too1
  • HAE guidelines recommend reviewing management plans for patients with HAE, including the need to start or continue a preventive treatment1

Want to learn about one preventive treatment option?

Extended care team

HAE is typically managed by allergy/immunology specialists. But because HAE can affect various areas of the body and symptoms and triggers vary, it can be different for every patient.1-5 Make sure your patient’s entire care team is aware of HAE, your patient’s symptoms and triggers, as well as the impact it has on their life.

The following healthcare providers should be kept informed of developments in the management of a patient’s HAE:

Stethoscope icon.

Primary care physicians, including pediatricians1,6

GI tract icon.

Gastroenterologists7

Tooth icon.

Dentists and oral surgeons1

Doctor icon.

Obstetricians and gynecologists1

Patients with HAE may develop increased anxiety and depression associated with the unpredictability, frequency, and severity of attacks. Talk with your patient about leveraging a mental health specialist to help them cope with their diagnosis or the stress of living with and managing HAE.3

Hazard icon.

Work with your patient's larger care team to advocate for an effective management plan that prevents and reduces HAE attacks.

Blue ring bell icon.

Have questions?

To learn more about how to help patients manage their HAE, submit a request and a Takeda representative will get in touch with you.

References:

  1. Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132-150. doi:10.1016/j.jaip.2020.08.046
  2. Banerji A. The burden of illness in patients with hereditary angioedema. Ann Allergy Asthma Immunol. 2013;111(5):329-336.
  3. Banerji A, Davis KH, Brown TM, et al. Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States. Ann Allergy Asthma Immunol. 2020;124(6):600-607.
  4. Agostoni A, Aygören-Pürsün E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114(Suppl 3):S51-S131.
  5. Nielsen EW, Gran JT, Straume B, Mellbye OJ, Johansen HT, Mollnes TE. Hereditary angio-oedema: new clinical observations and autoimmune screening, complement and kallikrein-kinin analyses. J Intern Med. 1996;239(2):119-130.
  6. Johnston DT, Smith RC. Hereditary angioedema: special considerations in children. Allergy Asthma Proc. 2020;41(Suppl 1):S43-S46. doi:10.2500/aap.2020.41.200042
  7. Mormile I, Cocchiaro A, Bova M, et al. Gastrointestinal manifestations of angioedema: a potential area of misdiagnosis. Eur J Gastroenterol Hepatol. 2021;33(6):787-793. doi:10.1097/MEG.0000000000001848